These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15508098)

  • 1. Prevention of hepatitis B virus-related hepatocellular carcinoma.
    Lok AS
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S303-9. PubMed ID: 15508098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
    J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
    Lok AS
    J Gastroenterol Hepatol; 2011 Feb; 26(2):221-7. PubMed ID: 21070361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
    World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Before and After Hepatocellular Carcinoma.
    Harputluoglu M; Carr BI
    J Gastrointest Cancer; 2021 Dec; 52(4):1206-1210. PubMed ID: 34762265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination.
    Kim MN; Han KH; Ahn SH
    Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF
    Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.
    Tawada A; Kanda T; Imazeki F; Yokosuka O
    Hepatol Int; 2016 Jul; 10(4):574-93. PubMed ID: 27026375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy.
    Halegoua-De Marzio D; Hann HW
    Minerva Gastroenterol Dietol; 2014 Sep; 60(3):191-200. PubMed ID: 25000955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chronic hepatitis B infection.
    Sundaram V; Kowdley K
    BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.
    Lai CL; Yuen MF
    Hepatology; 2013 Jan; 57(1):399-408. PubMed ID: 22806323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
    Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
    Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.